Sofwave Medical Ltd reported a 56% revenue increase and $1 million in net income for the third quarter of 2025.
Sofwave Medical Ltd reported $21.1 million in revenue for the third quarter of 2025, representing 56% year-over-year growth. Recurring revenue for the quarter reached $8.3 million, a 55% increase, making up 40% of total revenue.
Gross profit for the third quarter was $15.5 million, a 53% increase from the same period in 2024. Gross margin stood at 73.7%. Operating income was $1.5 million on an IFRS basis and $1.9 million on a non-IFRS basis. Net income was $1.0 million IFRS and $1.4 million non-IFRS. Cash flow was $2.5 million, up from $0.2 million in the prior-year quarter.
Revenue for the first 9 months of 2025 totaled $58.7 million, a 42% increase over the same period last year. Recurring revenue was $24.5 million, up 52%. Year-to-date net income was $1.4 million IFRS and $3.2 million non-IFRS. The company ended the quarter with $26.5 million in cash and cash equivalents.
“Sofwave delivered exceptional third quarter results, achieving record revenue during what is historically the med-device aesthetics industry’s slowest quarter,” said Louis Scafuri, CEO of Sofwave. “We achieved our second consecutive quarter of positive IFRS net income and generated $2.5 million in cash flow.”
Dr Shimon Eckhouse, chairman and co-founder, said, “Sofwave’s record quarterly revenue is a powerful testament to our disruptive technology and the value we deliver to patients and providers alike.”
Sofwave received FDA clearance for its Pure Impact VIP EMS device and has conducted approximately 667,000 treatments since commercialization. The company expects to achieve net profitability for the full year.
Photo: ID 5610720 © Gualtiero Boffi | Dreamstime.com
